Diffusion-weighted imaging of the liver: An update

Cancer Imaging

Volumn 13, Issue 2, 2013, Pages 171-185

  Bharwani, Nishat ^a   Koh, D M ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Diffusion weighted magnetic resonance imaging; Liver

Indexed keywords

CANCER GRADING; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FATTY LIVER; HEMOCHROMATOSIS; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

DIFFUSION MAGNETIC RESONANCE IMAGING; FATTY LIVER; HEMOCHROMATOSIS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; NEOPLASM GRADING;

EID: 84877842287     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.0019     Document Type: Review

References (100)

1. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006; 21: 1104-1108. doi:10.1093/ndt/gfk062. PMid:16431890.
2. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast- enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17: 2359-2362. doi:10.1681/ASN. 2006060601. PMid:16885403. (Pubitemid 44300951)
3. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007; 243: 148-157. doi:10.1148/radiol.2431062144. PMid:17267695. (Pubitemid 46579705)
4. Thomsen HS, Marckmann P, Logager VB. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin North Am 2008; 16: 551-560, vii. doi:10.1016/j.mric.2008.07.011.
5. Nicholson C, Phillips JM. Ion diffusion modified by tortuosity and volume fraction in the extracellular microenvironment of the rat cerebellum. J Physiol 1981; 321: 225-257. PMid:7338810. (Pubitemid 12248093)
6. Szafer A, Zhong J, Anderson AW, Gore JC. Diffusion-weighted imaging in tissues: theoretical models. NMR Biomed 1995; 8: 289-296. doi:10.1002/nbm. 1940080704. PMid:8739267.
7. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-125. PMid:19186405.
8. Koh DM, Collins DJ, Wallace T, Chau I, Riddell AM. Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases. Br J Radiol 2012; 85: 980-989. doi:10.1259/bjr/ 91771639. PMid:22167501.
9. Namimoto T, Yamashita Y, Sumi S, Tang Y, Takahashi M. Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 1997; 204: 739-744. PMid:9280252. (Pubitemid 27369034)
10. Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology 2010; 254: 47-66. doi:10.1148/radiol.09090021. PMid:20032142.
11. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003; 226: 71-78. doi:10.1148/radiol.2261011904. PMid:12511671. (Pubitemid 36163910)
12. Bruegel M, Holzapfel K, Gaa J, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 2008; 18: 477-485. doi:10.1007/s00330-007-0785-9. PMid:17960390. (Pubitemid 351248179)
13. Parikh T, Drew SJ, Lee VS, et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008; 246: 812-822. doi:10.1148/radiol.2463070432. PMid:18223123.
14. Gourtsoyianni S, Papanikolaou N, Yarmenitis S, Maris T, Karantanas A, Gourtsoyiannis N. Respiratory gated diffusionweighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol 2008; 18: 486-492. doi:10.1007/s00330-007-0798-4. PMid:17994317.
15. Kwee TC, Takahara T, Koh DM, Nievelstein RA, Luijten PR. Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging 2008; 28: 1141-1148. doi:10.1002/jmri.21569. PMid:18972355.
16. Braithwaite AC, Dale BM, Boll DT, Merkle EM. Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology 2009; 250: 459-465. doi:10.1148/radiol.2502080849. PMid:19095786.
17. Rosenkrantz AB, Oei M, Babb JS, Niver BE, Taouli B. Diffusionweighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla. J Magn Reson Imaging 2011; 33: 128-135. doi:10.1002/ jmri.22395. PMid:21182130.
18. Kim SY, Lee SS, Byun JH, et al. Malignant hepatic tumors: shortterm reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology 2010; 255: 815-823. doi:10.1148/ radiol.10091706. PMid:20501719.
19. Malyarenko D, Galban CJ, Londy FJ, et al. Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging 2012, doi:10.1002/jmri.23825.
20. Andreou A, Koh DM, Collins DJ, et al. Measurement reproducibility of perfusion fraction and pseudodiffusion coefficient derived by intravoxel incoherent motion diffusion-weighted MR imaging in normal liver and metastases. Eur Radiol 2013; 23: 428-434. doi:10.1007/s00330-012-2604-1. PMid:23052642.
21. Colagrande S, Pasquinelli F, Mazzoni LN, Belli G, Virgili G. MRdiffusion weighted imaging of healthy liver parenchyma: repeatability and reproducibility of apparent diffusion coefficient measurement. J Magn Reson Imaging 2010; 31: 912-920. doi:10.1002/jmri.22117. PMid:20373436.
22. Koh DM, Blackledge M, Collins DJ, et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009; 19: 2728-2738. doi:10.1007/s00330-009-1469-4. PMid:19547986.
23. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-525. PMid:2869260. (Pubitemid 16138427)
24. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906. doi:10.1053/j.gastro.2005.03.084. PMid:15940625. (Pubitemid 40824701)
25. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500. doi:10.1056/NEJM200102153440706. PMid:11172192. (Pubitemid 32164902)
26. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986; 2: 165-173. doi:10.1016/S0168-8278(86)80075-7. PMid:3958472. (Pubitemid 16125908)
27. Amano Y, Kumazaki T, Ishihara M. Single-shot diffusionweighted echo-planar imaging of normal and cirrhotic livers using a phased-array multicoil. Acta Radiol 1998; 39: 440-442. PMid:9685834. (Pubitemid 128451563)
28. Taouli B, Chouli M, Martin AJ, Qayyum A, Coakley FV, Vilgrain V. Chronic hepatitis: role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging 2008; 28: 89-95. doi:10.1002/jmri.21227. PMid:18581382. (Pubitemid 351956470)
29. Taouli B, Tolia AJ, Losada M, et al. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol 2007; 189: 799-806. doi:10.2214/AJR.07.2086. PMid:17885048. (Pubitemid 47479760)
30. Koinuma M, Ohashi I, Hanafusa K, Shibuya H. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 2005; 22: 80-85. doi:10.1002/jmri.20344. PMid:15971188. (Pubitemid 40885132)
31. Girometti R, Furlan A, Bazzocchi M, et al. Diffusion-weighted MRI in evaluating liver fibrosis: a feasibility study in cirrhotic patients. Radiol Med 2007; 112: 394-408. doi:10.1007/s11547- 007-0149-1. PMid:17440695. (Pubitemid 46663985)
32. Lewin M, Poujol-Robert A, Boelle PY, et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007; 46: 658-665. doi:10.1002/hep.21747. PMid:17663420. (Pubitemid 47436110)
33. Naganawa S, Kawai H, Fukatsu H, et al. Diffusion-weighted imaging of the liver: technical challenges and prospects for the future. Magn Reson Med Sci 2005; 4: 175-186. doi:10.2463/ mrms.4.175. PMid:16543702.
34. Aube C, Racineux PX, Lebigot J, et al. [Diagnosis and quantification of hepatic fibrosis with diffusion weighted MR imaging: preliminary results]. J Radiol 2004; 85: 301-306. doi:10.1016/ S0221-0363(04)97582-8. PMid:15192522. (Pubitemid 38797178)
35. Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010; 31: 589-600. doi:10.1002/jmri.22081. PMid:20187201.
36. Luciani A, Vignaud A, Cavet M, et al. Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 2008; 249: 891-899. doi:10.1148/ radiol.2493080080. PMid:19011186.
37. Fujimoto K, Tonan T, Azuma S, et al. Evaluation of the mean and entropy of apparent diffusion coefficient values in chronic hepatitis C: correlation with pathologic fibrosis stage and inflammatory activity grade. Radiology 2011; 258: 739-748. doi:10.1148/radiol.10100853. PMid:21248235.
38. Benedict RH, Bruce J, Dwyer MG, et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler 2007; 13: 722-730. doi:10.1177/ 1352458507075592. PMid:17613599. (Pubitemid 47074094)
39. Tavazzi E, Dwyer MG, Weinstock-Guttman B, et al. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage 2007; 36: 746-754. doi:10.1016/j.neuroimage.2007.03.056. PMid:17498974. (Pubitemid 46907634)
40. Wignall O, Scurr E, Collins D, Thng C-H, Koh DM. Hepatic steatosis results in a reduction in the apparent diffusion coefficient (ADC) of liver parenchyma. Abstract. 2008 Conference Proceedings for the ISMRM 16th Scientific Meeting Exhibition.
41. Poyraz AK, Onur MR, Kocakoc E, Ogur E. Diffusion-weighted MRI of fatty liver. J Magn Reson Imaging 2012; 35: 1108-1111. doi:10.1002/jmri.23519. PMid:22170763.
42. d-Assignies G, Ruel M, Khiat A, et al. Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods. Eur Radiol 2009; 19: 2033-2040. doi:10.1007/ s00330-009-1351-4. PMid:19280194.
43. Zech CJ, Herrmann KA, Dietrich O, Horger W, Reiser MF, Schoenberg SO. Black-blood diffusion-weighted EPI acquisition of the liver with parallel imaging: comparison with a standard T2-weighted sequence for detection of focal liver lesions. Invest Radiol 2008; 43: 261-266. doi:10.1097/ RLI.0b013e31816200b5. PMid:18340250. (Pubitemid 351416769)
44. Coenegrachts K, Orlent H, ter Beek L, et al. Improved focal liver lesion detection: comparison of single-shot spin-echo echoplanar and superparamagnetic iron oxide (SPIO)-enhanced MRI. J Magn Reson Imaging 2008; 27: 117-124. doi:10.1002/jmri.21247. PMid:18050350.
45. van den Bos IC, Hussain SM, Krestin GP, Wielopolski PA. Liver imaging at 3.0 T: diffusion-induced black-blood echo-planar imaging with large anatomic volumetric coverage as an alternative for specific absorption rate-intensive echo-train spin-echo sequences: feasibility study. Radiology 2008; 248: 264-271. doi:10.1148/radiol.2481070034. PMid:18566178.
46. Okada Y, Ohtomo K, Kiryu S, Sasaki Y. Breath-hold T2- weighted MRI of hepatic tumors: value of echo planar imaging with diffusion-sensitizing gradient. J Comput Assist Tomogr 1998; 22: 364-371. doi:10.1097/00004728- 199805000-00005. PMid:9606375. (Pubitemid 28396727)
47. Hussain SM, De Becker J, Hop WC, Dwarkasing S, Wielopolski PA. Can a single-shot black-blood T2-weighted spin-echo echo-planar imaging sequence with sensitivity encoding replace the respiratory-triggered turbo spin-echo sequence for the liver? An optimization and feasibility study. J Magn Reson Imaging 2005; 21: 219-229. doi:10.1002/jmri.20269. PMid:15723376. (Pubitemid 40280115)
48. Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003; 226: 71-78. doi:10.1148/radiol.2261011904. PMid:12511671. (Pubitemid 36163910)
49. Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR Am J Roentgenol 1999; 173: 393-398. doi:10.2214/ajr.173.2.10430143. PMid:10430143. (Pubitemid 29347365)
50. Coenegrachts K, Delanote J, ter Beek L, et al. Improved focal liver lesion detection: comparison of single-shot diffusionweighted echoplanar and single-shot T2 weighted turbo spin echo techniques. Br J Radiol 2007; 80: 524-531. doi:10.1259/ bjr/33156643. PMid:17510250. (Pubitemid 47343080)
51. Bruegel M, Gaa J, Waldt S, et al. Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echoplanar MRI and five t2-weighted turbo spin-echo sequences. AJR Am J Roentgenol 2008; 191: 1421-1429. doi:10.2214/ AJR.07.3279. PMid:18941080.
52. Nasu K, Kuroki Y, Nawano S, et al. Hepatic metastases: diffusion- weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006; 239: 122-130. doi:10.1148/ radiol.2383041384. PMid:16493012.
53. Low RN, Gurney J. Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging 2007; 25: 848-858. doi:10.1002/jmri.20864. PMid:17335018. (Pubitemid 46516739)
54. Koh DM, Brown G, Riddell AM, et al. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusionweighted imaging (DWI) alone and in combination. Eur Radiol 2008; 18: 903-910. doi:10.1007/s00330-007-0847-z. PMid:18193234.
55. Holzapfel K, Eiber MJ, Fingerle AA, Bruegel M, Rummeny EJ, Gaa J. Detection, classification, and characterization of focal liver lesions: value of diffusion-weighted MR imaging, gadoxetic acid-enhanced MR imaging and the combination of both methods. Abdom Imaging 2012; 37: 74-82. doi:10.1007/s00261- 011- 9758-1. PMid:21597893.
56. Kiryu S, Watanabe M, Kabasawa H, Akahane M, Aoki S, Ohtomo K. Evaluation of super paramagnetic iron oxideenhanced diffusion-weighted PROPELLER T2-fast spin echo magnetic resonance imaging: preliminary experience. J Comput Assist Tomogr 2006; 30: 197-200. doi:10.1097/ 00004728-200603000-00005. PMid:16628031. (Pubitemid 43739295)
57. Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Diffusion-weighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. AJR Am J Roentgenol 1998; 170: 397-402. doi:10.2214/ajr.170.2.9456953. PMid:9456953. (Pubitemid 28083846)
58. Koh DM, Scurr E, Collins DJ, et al. Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging. Eur Radiol 2006; 16: 1898-1905. doi:10.1007/s00330-006-0201-x. PMid:16691378. (Pubitemid 44193174)
59. Agnello F, Ronot M, Valla DC, Sinkus R, Van Beers BE, Vilgrain V. High-b-value diffusion-weighted MR imaging of benign hepatocellular lesions: quantitative and qualitative analysis. Radiology 2012; 262: 511-519. doi:10.1148/ radiol.11110922. PMid:22143926.
60. Battal B, Kocaoglu M, Akgun V, et al. Diffusion-weighted imaging in the characterization of focal liver lesions: efficacy of visual assessment. J Comput Assist Tomogr 2011; 35: 326-331. doi:10.1097/RCT.0b013e318216efeb. PMid:21586924.
61. Nasu K, Kuroki Y, Tsukamoto T, Nakajima H, Mori K, Minami M. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol 2009; 193: 438-444. doi:10.2214/AJR.08.1424. PMid:19620441.
62. Nishie A, Tajima T, Asayama Y, et al. Diagnostic performance of apparent diffusion coefficient for predicting histological grade of hepatocellular carcinoma. Eur J Radiol 2011; 80: e29-e33. doi:10.1016/j.ejrad.2010.06.019. PMid:20619566.
63. Nakanishi M, Chuma M, Hige S, et al. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol 2012; 19: 1302-1309. doi:10.1245/s10434-011-2066-8. PMid:21927976.
64. Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, Vilgrain V. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol 2011; 55: 126-132. doi:10.1016/j.jhep.2010.10.023. PMid:21145857.
65. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247. doi:10.1016/ j.ejca.2008.10.026. PMid:19097774.
66. Sharma U, Danishad KK, Seenu V, Jagannathan NR. Longitudinal study of the assessment by MRI and diffusionweighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 2009; 22: 104-113. doi:10.1002/nbm.1245. PMid:18384182.
67. Koh DM, Scurr E, Collins D, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007; 188: 1001-1008. doi:10.2214/AJR.06.0601. PMid:17377036. (Pubitemid 46496932)
68. Cui Y, Zhang XP, Sun YS, Tang L, Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248: 894-900. doi:10.1148/ radiol.2483071407. PMid:18710982.
69. Schraml C, Schwenzer NF, Clasen S, et al. Navigator respiratory- triggered diffusion-weighted imaging in the follow-up after hepatic radiofrequency ablation-initial results. J Magn Reson Imaging 2009; 29: 1308-1316. doi:10.1002/jmri.21770. PMid:19418557.
70. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusionweighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003; 181: 708-710. doi:10.2214/ajr.181.3. 1810708. PMid:12933464. (Pubitemid 37021839)
71. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2006; 17: 505-512. doi:10.1097/ 01.RVI.0000200052.02183.92. PMid:16567675. (Pubitemid 44318722)
72. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18: 49-56. doi:10.1016/j.jvir.2006.10.005. PMid:17296704. (Pubitemid 46616678)
73. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009; 250: 466-473. doi:10.1148/radiol.2502072222. PMid:19188315.
74. Chen CY, Li CW, Kuo YT, et al. Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants-initial experience. Radiology 2006; 239: 448-456. doi:10.1148/ radiol.2392042202. PMid:16569781.
75. Deng J, Miller FH, Rhee TK, et al. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 2006; 17: 1195-1200. doi:10.1097/01.RVI.0000227234.81718.EB. PMid:16868174. (Pubitemid 44318703)
76. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002; 360: 307-308. doi:10.1016/S0140-6736(02)- 09520-X. PMid:12147376. (Pubitemid 34874724)
77. Do RK, Chandarana H, Felker E, et al. Diagnosis of liver fibrosis and cirrhosis with diffusion-weighted imaging: value of normalized apparent diffusion coefficient using the spleen as reference organ. AJR Am J Roentgenol 2010; 195: 671-676. doi:10.2214/AJR.09.3448. PMid:20729445.
78. Sandrasegaran K, Akisik FM, Lin C, et al. Value of diffusionweighted MRI for assessing liver fibrosis and cirrhosis. AJR Am J Roentgenol 2009; 193: 1556-1560. doi:10.2214/AJR.09.2436. PMid:19933647.
79. Bulow R, Mensel B, Meffert P, Hernando D, Evert M, Kuhn JP. Diffusion-weighted magnetic resonance imaging for staging liver fibrosis is less reliable in the presence of fat and iron. Eur Radiol 2012; doi:10.1007/s00330- 012-2700-2.
80. Tosun M, Inan N, Sarisoy HT, et al. Diagnostic performance of conventional diffusion weighted imaging and diffusion tensor imaging for the liver fibrosis and inflammation. Eur J Radiol 2013; 82: 203-207. doi:10.1016/j.ejrad.2012.09.009. PMid:23122674.
81. Kovac JD, Dakovic M, Stanisavljevic D, et al. Diffusionweighted MRI versus transient elastography in quantification of liver fibrosis in patients with chronic cholestatic liver diseases. Eur J Radiol 2012; 81: 2500-2506. doi:10.1016/ j.ejrad.2011.10.024. PMid:22100369.
82. Bakan AA, Inci E, Bakan S, Gokturk S, Cimilli T. Utility of diffusion-weighted imaging in the evaluation of liver fibrosis. Eur Radiol 2012; 22: 682-687. doi:10.1007/s00330-011-2295- z. PMid:21984447.
83. Bonekamp S, Torbenson MS, Kamel IR. Diffusion-weighted magnetic resonance imaging for the staging of liver fibrosis. J Clin Gastroenterol 2011; 45: 885-892. doi:10.1097/ MCG.0b013e318223bd2c. PMid:21716125.
84. Soylu A, Kilickesmez O, Poturoglu S, et al. Utility of diffusionweighted MRI for assessing liver fibrosis in patients with chronic active hepatitis. Diagn Interv Radiol 2010; 16: 204-208. PMid:20658448.
85. Mwangi I, Hanna RF, Kased N, et al. Apparent diffusion coefficient of fibrosis and regenerative nodules in the cirrhotic liver at MRI. AJR Am J Roentgenol 2010; 194: 1515-1522. doi:10.2214/AJR.09.3484. PMid:20489091.
86. Wang QB, Zhu H, Liu HL, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: a meta-analysis. Hepatology 2012; 56: 239-247. doi:10.1002/hep.25610. PMid:22278368.
87. Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion- weighted MR imaging-preliminary observations. Radiology 2011; 259: 142-150. doi:10.1148/radiol.10100621. PMid:21248234.
88. Yang DM, Jahng GH, Kim HC, et al. The detection and discrimination of malignant and benign focal hepatic lesions: T2 weighted vs diffusion-weighted MRI. Br J Radiol 2011; 84: 319-326. doi:10.1259/bjr/50130643. PMid:20959371.
89. Coenegrachts K, Matos C, ter Beek L, et al. Focal liver lesion detection and characterization: comparison of non-contrast enhanced and SPIO-enhanced diffusion-weighted single-shot spin echo planar and turbo spin echo T2-weighted imaging. Eur J Radiol 2009; 72: 432-439. doi:10.1016/ j.ejrad.2008.09.005. PMid:18849130.
90. Bruegel M, Holzapfel K, Gaa J, et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 2008; 18: 477-485. doi:10.1007/s00330- 007-0785-9. PMid:17960390. (Pubitemid 351248179)
91. Goshima S, Kanematsu M, Kondo H, et al. Diffusion-weighted imaging of the liver: optimizing b value for the detection and characterization of benign and malignant hepatic lesions. J Magn Reson Imaging 2008; 28: 691-697. doi:10.1002/ jmri.21467. PMid:18777553.
92. Coenegrachts K, Delanote J, Ter Beek L, et al. Improved focal liver lesion detection: comparison of single-shot diffusionweighted echoplanar and single-shot T2 weighted turbo spin echo techniques. Br J Radiol 2007; 80: 524-531. doi:10.1259/ bjr/33156643. PMid:17510250. (Pubitemid 47343080)
93. Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Characterization of hepatic lesions by perfusion-weighted MR imaging with an echoplanar sequence. AJR Am J Roentgenol 1998; 170: 1029-1034. doi:10.2214/ajr.170.4.9530054. PMid:9530054. (Pubitemid 28172893)
94. Song KD, Kim YK, Lee WJ, et al. Detection and characterization of small focal hepatic lesions (52.5 cm in diameter): a comparison of diffusion-weighted images before and after administration of gadoxetic acid disodium at 3.0T. Acta Radiol 2012; 53: 485-493. doi:10.1258/ar.2012.110437. PMid:22535883.
95. Kim YK, Lee MW, Lee WJ, et al. Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (5 1.5 cm in diameter). Invest Radiol 2012; 47: 159-166. PMid:22330426.
96. Chung WS, Kim MJ, Chung YE, et al. Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J Magn Reson Imaging 2011; 34: 345-353. doi:10.1002/ jmri.22671. PMid:21702068.
97. Lowenthal D, Zeile M, Lim WY, et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 2011; 21: 832-840. doi:10.1007/ s00330-010-1977-2. PMid:20886339.
98. Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K. Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol 2010; 20: 2690-2698. doi:10.1007/ s00330-010-1842-3. PMid:20563726.
99. Nasu K, Kuroki Y, Kuroki S, Murakami K, Nawano S, Moriyama N. Diffusion-weighted single shot echo planar imaging of colorectal cancer using a sensitivity-encoding technique. Jpn J Clin Oncol 2004; 34: 620-626. doi:10.1093/jjco/hyh108. PMid:15591461. (Pubitemid 40662718)
100. Cieszanowski A, Szeszkowski W, Golebiowski M, Bielecki DK, Grodzicki M, Pruszynski B. Discrimination of benign from malignant hepatic lesions based on their T2-relaxation times calculated from moderately T2-weighted turbo SE sequence. Eur Radiol 2002; 12: 2273-2279. PMid:12195480. (Pubitemid 36940323)